GSK/Theravance Breo wins easy breezy FDA panel nod
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's and Theravance's experimental chronic obstructive pulmonary disease (COPD) drug Breo (fluticasone furoate 100mcg/vilanterol 25mcg) had an easy go before the FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) on 17 April, with the panel backing the safety and effectiveness of the drug.